查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1351068

2030 年核子醫學市場預測：依部門市場和地區分類的全球分析

Nuclear Medicine Market Forecasts to 2030 - Global Analysis By Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球核醫學市場規模為 103 億美元，預計預測期內年複合成長率為 13.8%，到 2030 年將達到 255 億美元。

核子醫學是領域。核子醫學主要用於需要核子醫學診斷和治療的各種疾病。放射性藥物用於治療。多種疾病都需要這種類型的治療，包括甲狀腺亢進、各種形式的骨痛和甲狀腺癌。

據美國心臟協會稱，2020 年全球約有 1,910 萬人死於 CVD。每10萬人口年齡調整死亡率為239.8，年齡調整患病7,354.1。

癌症和心臟疾病患病上升

這種增加的疾病負擔需要先進的診斷和治療方案，其中核子醫學發揮關鍵作用。核子醫學提供準確、早期疾病檢測、精確治療監測和標靶治療的能力正在引起醫療保健提供者和患者的注意。因此，隨著健康課題的加劇，對高效和個體化醫療保健解決方案的需求不斷成長，刺激了核醫學領域的擴張，推動創新和市場發展。

診斷及治療設備及程序高成本

核子醫學影像和治療所需的複雜技術和專用材料導致初期成本急劇上升。此外，對熟練人員、維護和法規遵循的需求進一步增加了經濟負擔。這些高成本阻礙了核子醫學服務的取得，並限制了採用率，特別是在資源有限的醫療保健系統中。解決負擔能力問題將確保核醫學的廣泛使用，因為在不犧牲品質的情況下降低成本仍然是市場擴張和公平醫療保健提供的關鍵因素。這樣做極為重要。

對影像導引手術和診斷的需求不斷增加

許多大公司和醫學都採用了核子醫學，因為它改善了他們的生產流程。這些系統能夠提高產量、降低成本、提高品質並實現即時資料收集和產品監控，從而提高生產效率。這方面有望鼓勵使用這些系統來增加收益。核子醫學的使用也減少了整個生產過程中的廢棄物和能源使用量。例如，在製造車間安裝 MES 解決方案可以消除對文書工作和實體儲存空間的需求，同時也消除了對額外 IT 資源的需求。

嚴格的法規指引

隨著產業的發展，遵守複雜且不斷變化的法規變得至關重要。這些指南包括安全性、有效性和倫理考慮，並且通常要求新技術和放射性藥物經過嚴格的測試和核准流程。合規性所需的時間和資源可能會阻礙創新、延遲產品發布並增加開發成本。滿足這些要求的努力可能會阻止新進入者並限制市場成長。因此，應對法規限制的迷宮已成為一項重大課題，可能阻礙核醫學解決方案的快速發展。

COVID-19 的影響：

COVID-19的爆發對核醫學市場產生了重大影響。由於資源重新分配和安全問題，選擇性手術和常規影像面臨延遲，導致患者數量下降。供應鏈中斷影響了放射性藥物和設備的可得性，導致市場波動。然而，這場危機凸顯了核子醫學在疾病快速診斷和治療監測方面的價值。遠端醫療和遠距報告已普及，服務提供也已重組。

預測期內正子斷層掃描（PET）應用領域預計最大

正子斷層掃描（PET）應用領域預計將出現良好的成長。 PET 可實現體內代謝和功能過程的精確視覺化和量化。 PET 對腫瘤學至關重要，有助於早期發現癌症、準確分期並監測治療效果。在神經病學中，PET 掃描可用於診斷阿茲海默症和癲癇等腦部疾病。心血管疾病是透過 PET 評估血流和心臟功能的能力來評估的。此外，PET 有助於新放射性藥物的開發並支持藥物研發研究。 PET 的非侵入性和定量資料使其成為推進個體化和有針對性的醫療干預的基石。

預計醫院領域在預測期內的年複合成長率最高。

預計醫院領域在預測期內將以最快的年複合成長率成長。核子醫學市場的醫院是診斷、治療和研究的主要中心。醫院配備了 PET、SPECT 和伽馬相機等先進的影像設備，提供核子醫學的基本服務。為廣大患者提供準確的疾病檢測、準確的分期和治療監測。醫院內的核子醫學部門與多學科團隊合作，通常將影像學與其他醫學領域整合，以加強患者照護。此外，醫院也為創新放射性藥物和影像技術的開發和評估做出了重大貢獻，促進核子醫學的持續進步，改善病患的治療效果。

佔比最大的地區：

在預測期內，由於其先進的醫療基礎設施和研究能力，北美核醫學市場預計將繼續佔據大部分市場佔有率。該地區成熟的醫療設施和學術機構推動了成像技術和放射性藥物開發的創新。癌症和心血管疾病等慢性病的高罹患率正在推動對核醫學服務的需求。北美強大的法規結構確保了安全和品質標準。主要市場參與者的存在、與研究機構的合作以及醫療保健投資的增加有助於該地區在核醫學的領導地位，使其成為尖端診斷和治療應用的中心。

複合年複合成長率最高的地區：

由於醫療保健投資的增加、疾病早期檢測意識的提高以及老年人口的成長推動了對尖端診斷和治療解決方案的需求，亞太地區在預測期內將出現最高的年複合成長率，預計這種情況將會發生。該地區擴大醫療基礎設施和改善經濟狀況正在推動核醫學技術的採用。此外，亞太地區多樣化的患者群體為臨床研究和臨床試驗提供了充足的機會，有助於創新放射性藥物和影像技術的研究和開發。憑藉新興市場和技術進步的結合，亞太地區有望在塑造核醫學的未來方面發揮關鍵作用。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球核子醫學市場：依類型

  • 診斷核子醫學
    • 單光子發射電腦斷層掃描 (SPECT) 放射性藥物
      • 锝-99m
      • 碘123
      • 鉈201
      • 鎵67
    • 正子斷層掃描 (PET) 放射性藥物
      • 氟18
      • 銣82
  • 治療性核子醫學
    • 阿爾法發射器
      • 鐳223
    • BETA放射體
      • 碘131
      • 釔90
      • 釤-153
      • 鎦-177
      • 錸186
  • 近距離放射同位素
    • 碘125
    • 銥192
    • 鈀103
    • 銫131
  • 其他類型

第6章 全球核子醫學市場：依用途

  • 診斷用途
    • 單光子發射電腦斷層掃描 (SPECT) 應用
      • 心臟病學
      • 骨骼掃描
      • 甲狀腺的應用
      • 肺部掃描
    • 正子斷層掃描（PET）的應用
      • 腫瘤學
      • 心臟病學
      • 神經病學
    • 治療應用
      • 甲狀腺適應症
      • 骨轉移
      • 淋巴瘤
      • 內分泌腫瘤
  • 其他用途

第7章 全球核子醫學市場：依最終使用者分類

  • 醫院
  • 影像中心
  • 學術研究中心
  • 其他最終用戶

第8章 全球核子醫學市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Isotopia Molecular Imaging Ltd.
  • Jubilant Draximage, Inc.
  • Lantheus Holdings, Inc.
  • Cardinal Health
  • Global Medical Solutions
  • Pharmalogic Holdings Corp.
  • Shine Technologies, llc
  • Ire Elit
  • Eczacibasi-Monrol Nuclear Products
  • GE Healthcare
  • Bayer AG
  • Bracco Imaging SPA
  • Nordion Inc.
  • Northstar Medical Radioisotopes
  • Isotope JSC
  • Siemens Healthineers
  • Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • Eckert & Ziegler
Product Code: SMRC23755

According to Stratistics MRC, the Global Nuclear Medicine Market is accounted for $10.3 billion in 2023 and is expected to reach $25.5 billion by 2030 growing at a CAGR of 13.8% during the forecast period. Nuclear medicine is a specialty that examines the structure, and occasionally the operation, of an organ in the human body using a very small amount of radiology or other radioactive elements. It is mostly utilized for various disorders that require nuclear medicine for diagnosis and treatment. Radiopharmaceuticals are utilized during the course of the treatment. This kind of treatment is required for a variety of conditions, including hyperthyroidism, various forms of bone pain, and thyroid cancer.

According to American Heart Association 2022, approximately 19.1 million deaths were attributed to CVD globally in 2020. The age-adjusted death rate per 100,000 population was 239.8 and age-adjusted prevalence rate was 7354.1 per 100,000.

Market Dynamics:

Driver:

Rise in prevalence of cancer and cardiac disorders

This rise in disease burden necessitates advanced diagnostic and treatment options, where nuclear medicine plays a pivotal role. The technique's ability to offer accurate and early disease detection, precise treatment monitoring, and targeted therapies has garnered attention from both healthcare providers and patients. As a result, the increasing demand for efficient and personalized healthcare solutions in the face of these mounting health challenges has spurred the expansion of the nuclear medicine sector, driving innovation and market advancement.

Restraint:

High cost of the diagnostic and therapeutic equipment and procedures

The intricate technologies and specialized materials required for nuclear imaging and treatments contribute to elevated upfront expenses. Moreover, the need for skilled personnel, maintenance, and regulatory compliance further amplifies the financial burden. These high costs can impede accessibility to nuclear medicine services, limiting adoption rates, particularly in resource-constrained healthcare systems. Addressing the affordability challenge becomes pivotal to ensuring wider utilization of nuclear medicine, as reducing costs without compromising quality remains a critical factor for market expansion and equitable healthcare delivery.

Opportunity:

Increasing demand for image guided procedures and diagnostics

Many major companies and SMEs are implementing Nuclear Medicine because they improve production processes. Production efficiency is aided by these systems' capacity to boost output, cut costs, boost quality, enabling real-time data collecting and monitoring of products. This aspect is anticipated to promote the use of these systems in order to boost revenues. The use of Nuclear Medicine also results in decreases in the amount of waste and energy used throughout the production process. For instance, putting a MES solution on a shop floor eliminates the need for paperwork and physical storage space while not requiring extra IT resources.

Threat:

Stringent regulatory guidelines

As the industry evolves, adherence to complex and evolving regulations becomes paramount. These guidelines encompass safety, efficacy, and ethical considerations, often requiring rigorous testing and approval processes for new technologies and radiopharmaceuticals. The time and resources needed for compliance can hinder innovation, delay product launches, and increase development costs. Struggling to meet these requirements might deter new entrants and limit market growth. Consequently, navigating the intricate landscape of regulatory constraints emerges as a substantial challenge, potentially impeding the swift advancement of nuclear medicine solutions.

COVID-19 Impact:

The COVID-19 pandemic had a significant impact on the nuclear medicine market. Elective procedures and routine imaging faced delays due to resource reallocation and safety concerns, leading to decreased patient volumes. Supply chain disruptions affected the availability of radiopharmaceuticals and equipment, causing fluctuations in the market. However, the crisis underscored the value of nuclear medicine for rapid disease diagnosis and treatment monitoring. Telemedicine and remote reporting gained traction, reshaping service delivery.

The positron emission tomography (pet) applications segment is expected to be the largest during the forecast period

The positron emission tomography (pet) applications segment is expected to have a lucrative growth. It enables precise visualization and quantification of metabolic and functional processes within the body. PET is crucial for oncology, aiding in early cancer detection, accurate staging, and monitoring treatment response. Neurology benefits from PET scans for diagnosing brain disorders like Alzheimer's and epilepsy. Cardiovascular diseases are assessed through PET's ability to evaluate blood flow and heart function. Moreover, PET facilitates the development of novel radiopharmaceuticals and supports research in drug discovery. Its non-invasive nature and quantitative data make PET a cornerstone for advancing personalized and targeted medical interventions.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. Hospitals in the nuclear medicine market serve as primary hubs for diagnosis, treatment, and research. Equipped with advanced imaging equipment like PET, SPECT, and gamma cameras, hospitals provide essential nuclear medicine services. They cater to a wide range of patients, offering precise disease detection, accurate staging, and therapy monitoring. Nuclear medicine departments within hospitals collaborate with multidisciplinary teams to enhance patient care, often integrating imaging with other medical specialties. Furthermore, hospitals contribute significantly to the development and evaluation of innovative radiopharmaceuticals and imaging techniques, fostering continuous advancements in nuclear medicine for improved patient outcomes.

Region with largest share:

During the forecast period, it is expected that the North American Nuclear Medicine market will continue to hold a majority of the market share due to its advanced healthcare infrastructure and research capabilities. The region's well-established medical facilities and academic institutions drive innovation in imaging technologies and radiopharmaceutical development. The high prevalence of chronic diseases, including cancer and cardiovascular disorders, fuels the demand for nuclear medicine services. North America's robust regulatory framework ensures safety and quality standards. The presence of key market players, collaborations with research organizations, and increasing investments in healthcare contribute to the region's leadership in nuclear medicine, making it a hub for cutting-edge diagnostic and therapeutic applications.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, due to its increasing healthcare investments, rising awareness of early disease detection, and a growing geriatric population drive the demand for advanced diagnostic and therapeutic solutions. The region's expanding healthcare infrastructure, coupled with improving economic conditions, fosters the adoption of nuclear medicine technologies. Moreover, Asia Pacific's diverse patient pool provides ample opportunities for clinical research and trials, contributing to the development of innovative radiopharmaceuticals and imaging techniques. With a blend of emerging markets and technological advancements, Asia Pacific is poised to play a significant role in shaping the future of nuclear medicine.

Key players in the market:

Some of the key players in Nuclear Medicine market include: Isotopia Molecular Imaging Ltd., Jubilant Draximage, Inc., Lantheus Holdings, Inc., Cardinal Health, Global Medical Solutions, Pharmalogic Holdings Corp., Shine Technologies, llc, Ire Elit, Eczacibasi-Monrol Nuclear Products, GE Healthcare, Bayer AG, Bracco Imaging S.P.A., Nordion Inc., Northstar Medical Radioisotopes, Isotope JSC, Siemens Healthineers, Yantai Dongcheng Pharmaceutical Group Co., Ltd. and Eckert & Ziegler.

Key Developments:

In March 2023, Life Healthcare acquired TheraMed Nuclear's non-clinical imaging operations in Gauteng with an aim to expand its geographical presence in South Africa.

In February 2023, Telix Pharmaceuticals Limited announced the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) in February 2021. This project aims to create and validate a generator-based theranostic compound for urologic oncology targeting PSMA and utilising the beta-emitting isotope rhenium-188 (188Re).

In January 2023, Nuclear medicines are a group of pharmaceutical drugs that contain radioactive isotopes. They are exclusive medicinal formulations with radioisotopes and are used in major clinical areas for diagnosis or therapy.

In November 2022, Curium announced that the US Food and Drug Administration (FDA) approved DaTscan (Ioflupane I 123 Injection) to assist in evaluating adult patients with suspected Parkinsonian Syndromes.

Types Covered:

  • Diagnostic Nuclear Medicine
  • Therapeutic Nuclear Medicine
  • Brachytherapy Isotopes
  • Other Types

Applications Covered:

  • Diagnostic Applications
  • Other Applications

End Users Covered:

  • Hospitals
  • Imaging Centers
  • Academic & Research Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nuclear Medicine Market, By Type

  • 5.1 Introduction
  • 5.2 Diagnostic Nuclear Medicine
    • 5.2.1 Single Photon Emission Computerized Tomography (SPECT) Radiopharmaceuticals
      • 5.2.1.1 Technetium-99m
      • 5.2.1.2 Iodine-123
      • 5.2.1.3 Thallium-201
      • 5.2.1.4 Gallium-67
    • 5.2.2 Positron Emission Tomography (PET) Radiopharmaceuticals
      • 5.2.2.1 Fluorine-18
      • 5.2.2.2 Rubidium-82
  • 5.3 Therapeutic Nuclear Medicine
    • 5.3.1 Alpha Emitters
      • 5.3.1.1 Radium-223
    • 5.3.2 Beta Emitters
      • 5.3.2.1 Iodine-131
      • 5.3.2.2 Yittrium-90
      • 5.3.2.3 Samarium-153
      • 5.3.2.4 Lutetium-177
      • 5.3.2.5 Rhenium-186
  • 5.4 Brachytherapy Isotopes
    • 5.4.1 Iodine-125
    • 5.4.2 Iridium-192
    • 5.4.3 Palladium-103
    • 5.4.4 Cesium-131
  • 5.5 Other Types

6 Global Nuclear Medicine Market, By Application

  • 6.1 Introduction
  • 6.2 Diagnostic Applications
    • 6.2.1 Single Photon Emission Computerized Tomography (SPECT) Applications
      • 6.2.1.2 Cardiology
      • 6.2.1.3 Bone Scans
      • 6.2.1.4 Thyroid Applications
      • 6.2.1.5 Pulmonary Scans
    • 6.2.2 Positron Emission Tomography (PET) Applications
      • 6.2.2.1 Oncology
      • 6.2.2.2 Cardiology
      • 6.2.2.3 Neurology
    • 6.2.3 Therapeutic Applications
      • 6.2.3.1 Thyroid Indications
      • 6.2.3.2 Bone Metastasis
      • 6.2.3.3 Lymphoma
      • 6.2.3.4 Endocrine Tumors
  • 6.3 Other Applications

7 Global Nuclear Medicine Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Imaging Centers
  • 7.4 Academic & Research Centers
  • 7.5 Other End Users

8 Global Nuclear Medicine Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Isotopia Molecular Imaging Ltd.
  • 10.2 Jubilant Draximage, Inc.
  • 10.3 Lantheus Holdings, Inc.
  • 10.4 Cardinal Health
  • 10.5 Global Medical Solutions
  • 10.6 Pharmalogic Holdings Corp.
  • 10.7 Shine Technologies, llc
  • 10.8 Ire Elit
  • 10.9 Eczacibasi-Monrol Nuclear Products
  • 10.10 GE Healthcare
  • 10.11 Bayer AG
  • 10.12 Bracco Imaging S.P.A.
  • 10.13 Nordion Inc.
  • 10.14 Northstar Medical Radioisotopes
  • 10.15 Isotope JSC
  • 10.16 Siemens Healthineers
  • 10.17 Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • 10.18 Eckert & Ziegler

List of Tables

  • Table 1 Global Nuclear Medicine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nuclear Medicine Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Nuclear Medicine Market Outlook, By Diagnostic Nuclear Medicine (2021-2030) ($MN)
  • Table 4 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computerized Tomography (SPECT) Radiopharmaceuticals (2021-2030) ($MN)
  • Table 5 Global Nuclear Medicine Market Outlook, By Technetium-99m (2021-2030) ($MN)
  • Table 6 Global Nuclear Medicine Market Outlook, By Iodine-123 (2021-2030) ($MN)
  • Table 7 Global Nuclear Medicine Market Outlook, By Thallium-201 (2021-2030) ($MN)
  • Table 8 Global Nuclear Medicine Market Outlook, By Gallium-67 (2021-2030) ($MN)
  • Table 9 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2021-2030) ($MN)
  • Table 10 Global Nuclear Medicine Market Outlook, By Fluorine-18 (2021-2030) ($MN)
  • Table 11 Global Nuclear Medicine Market Outlook, By Rubidium-82 (2021-2030) ($MN)
  • Table 12 Global Nuclear Medicine Market Outlook, By Therapeutic Nuclear Medicine (2021-2030) ($MN)
  • Table 13 Global Nuclear Medicine Market Outlook, By Alpha Emitters (2021-2030) ($MN)
  • Table 14 Global Nuclear Medicine Market Outlook, By Radium-223 (2021-2030) ($MN)
  • Table 15 Global Nuclear Medicine Market Outlook, By Beta Emitters (2021-2030) ($MN)
  • Table 16 Global Nuclear Medicine Market Outlook, By Iodine-131 (2021-2030) ($MN)
  • Table 17 Global Nuclear Medicine Market Outlook, By Yittrium-90 (2021-2030) ($MN)
  • Table 18 Global Nuclear Medicine Market Outlook, By Samarium-153 (2021-2030) ($MN)
  • Table 19 Global Nuclear Medicine Market Outlook, By Lutetium-177 (2021-2030) ($MN)
  • Table 20 Global Nuclear Medicine Market Outlook, By Rhenium-186 (2021-2030) ($MN)
  • Table 21 Global Nuclear Medicine Market Outlook, By Brachytherapy Isotopes (2021-2030) ($MN)
  • Table 22 Global Nuclear Medicine Market Outlook, By Iodine-125 (2021-2030) ($MN)
  • Table 23 Global Nuclear Medicine Market Outlook, By Iridium-192 (2021-2030) ($MN)
  • Table 24 Global Nuclear Medicine Market Outlook, By Palladium-103 (2021-2030) ($MN)
  • Table 25 Global Nuclear Medicine Market Outlook, By Cesium-131 (2021-2030) ($MN)
  • Table 26 Global Nuclear Medicine Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 27 Global Nuclear Medicine Market Outlook, By Application (2021-2030) ($MN)
  • Table 28 Global Nuclear Medicine Market Outlook, By Diagnostic Applications (2021-2030) ($MN)
  • Table 29 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computerized Tomography (SPECT) Applications (2021-2030) ($MN)
  • Table 30 Global Nuclear Medicine Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 31 Global Nuclear Medicine Market Outlook, By Bone Scans (2021-2030) ($MN)
  • Table 32 Global Nuclear Medicine Market Outlook, By Thyroid Applications (2021-2030) ($MN)
  • Table 33 Global Nuclear Medicine Market Outlook, By Pulmonary Scans (2021-2030) ($MN)
  • Table 34 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Applications (2021-2030) ($MN)
  • Table 35 Global Nuclear Medicine Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 36 Global Nuclear Medicine Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 37 Global Nuclear Medicine Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 38 Global Nuclear Medicine Market Outlook, By Therapeutic Applications (2021-2030) ($MN)
  • Table 39 Global Nuclear Medicine Market Outlook, By Thyroid Indications (2021-2030) ($MN)
  • Table 40 Global Nuclear Medicine Market Outlook, By Bone Metastasis (2021-2030) ($MN)
  • Table 41 Global Nuclear Medicine Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 42 Global Nuclear Medicine Market Outlook, By Endocrine Tumors (2021-2030) ($MN)
  • Table 43 Global Nuclear Medicine Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 44 Global Nuclear Medicine Market Outlook, By End User (2021-2030) ($MN)
  • Table 45 Global Nuclear Medicine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 Global Nuclear Medicine Market Outlook, By Imaging Centers (2021-2030) ($MN)
  • Table 47 Global Nuclear Medicine Market Outlook, By Academic & Research Centers (2021-2030) ($MN)
  • Table 48 Global Nuclear Medicine Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.